Erica Carbajal

Erica Carbajal is a journalist at Becker's Healthcare, where she covers healthcare industry news with a focus on hospital management and leadership. Prior to joining Becker's, Erica worked as a reporter for several local newspapers in the United States. Her articles often explore the challenges hospitals and health systems face in responding to emerging health threats, such as RSV, flu, and Covid-19 outbreaks. In addition to her reporting duties, Erica contributes to Becker's Healthcare's podcast series, 'Becker's Hospital Review,' where she discusses healthcare industry news and trends with industry leaders.

Biography:  https://www.beckershospitalreview.com/podcasts/podcasts-beckers-hospital-review/erica-carbajal-editor-at-becker-s-healthcare-92254224.html

72%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

75%

Examples:

  • Erica Carbajal reports on a study linking Ozempic to a rare eye condition that can cause blindness. The article does not disclose any potential conflicts of interest or financial ties to the drug's manufacturer.

Conflicts of Interest

95%

Examples:

  • The article does not disclose any potential conflicts of interest or financial ties to the drug's manufacturer.

Contradictions

100%

Examples:

No current examples available.

Deceptions

40%

Examples:

  • The article states that patients taking Ozempic and Wegovy were more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION), a condition that restricts blood flow to the optic nerve and causes sudden vision loss. However, it does not mention that the study found the risk of developing NAION was four times higher in diabetes patients taking semaglutide and seven times higher in obesity patients taking the drug, compared to those not taking it.

Recent Articles

New Study Links Semaglutide Use to Increased Risk of Optic Neuropathy: 17 Diabetes and 20 Obesity Patients Developed NAION While Taking the Drug

New Study Links Semaglutide Use to Increased Risk of Optic Neuropathy: 17 Diabetes and 20 Obesity Patients Developed NAION While Taking the Drug

Broke On: Wednesday, 03 July 2024 Semaglutide use linked to increased risk of vision loss, study finds, prompting caution for Ozempic and Wegovy patients.